NEW YORK, NY--(Marketwire - December 11, 2009) - Pulmo BioTech Inc. (OTCBB: PLMO) (FRANKFURT: PBO) has announced that it has successfully completed the final stages of
its experimental work required for Regulatory Approval to commence Phase I
Human Trials.
"With the successful completion of the 'Local reaction study' and the
'Binding studies with MCF-7 cells' we have now concluded all of the work
agreed with the Regulatory Authority as being necessary prior to commencing
our Phase I Trials. We are now completing and finalizing our documentation
packs prior to submitting our report to the Regulatory Authority for
permission to commence Phase I Human Trials of our PulmoBind™ pulmonary
imaging agent" -- Garry McCann, CEO Pulmo BioTech Inc.
About Pulmo BioTech Inc.
Pulmo BioTech Inc. specializes in the development and marketing of medical
technology and research. Our proven strengths combine extensive commercial
experience and academic credentials. The principal staff members are
acknowledged experts in their specialized fields, and work with a broad
range of investment institutions. Our mission is to utilize scientific
imagination and drive, together with managerial and financial acumen, to
bring innovative and profitable products to the marketplace to the benefit
of all stockholders.
ISIN: US7458451074
CUSIP: 745845107
WKN: A0RDTZ
About PulmoScience Inc.
PulmoScience Inc. was established in 2006, and is currently developing a
non-invasive Molecular Imaging technique for the diagnosis of Pulmonary
Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the
trade name PulmoBind™.
PulmoScience was conceived within the Montreal Heart Institute "MHI" (a
world renowned hospital and educational facility). Jointly owned by MHI
subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn
Dupuis (the scientific director and originator of the PulmoBind™
Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding
partner, PulmoScience Inc. aims to develop this unique and exciting
technology, to fund necessary trials, and to bring the products to market.
PulmoScience believes that the market for its product candidates is worth
in excess of $500 million per annum and that, provided Regulatory Approval
is achieved, the safety and efficacy of its products could allow it to
dominate that market.
About PulmoBind™
PulmoBind™ uses an intravenously delivered radionuclide tagged molecule
which specifically bonds to the inner walls of the circulatory system in
the lungs, and by the use of an external Gamma Camera allows an image of
the integrity of the blood vessels throughout the lungs to be seen by a
diagnostic clinician. PulmoScience is currently undertaking Regulatory
Approval for Phase I Human Trials, and while subsequent results from
additional tests might not corroborate the current results, PulmoScience
believes that PulmoBind™ has the potential to dominate the market for
the diagnosis of Pulmonary Embolism. In particular, this belief is driven
by PulmoScience's expectations of the improved safety and efficacy that
PulmoBind™ will offer when compared to the current incumbent nuclear
medicine based technology for the diagnosis of Pulmonary Embolism. In
addition, early indications are that PulmoBind™ could be highly
effective in the early stage diagnosis of Pulmonary Hypertension, a
condition for which there is no current front line diagnostic test. The
addressable market for the product candidates being developed by
PulmoScience is believed by the company to be worth in excess of $500
million per annum.
Further Information
For further information regarding Pulmo BioTech Inc. or PulmoScience,
please visit www.pulmobiotech.com
Forward-Looking Statements
Forward-looking statements contained in this and other written and oral
reports are made based on known events and circumstances at the time of
release, and as such, are subject in the future to unforeseen uncertainties
and risks. All statements regarding future performance, earnings
projections, regulatory approval, events or developments are
forward-looking statements. It is possible that the future performance of
the company may differ materially from current expectations, depending on
economic conditions and the uncertainty of regulatory approval. A change in
economic conditions may have a particularly volatile effect on results.
Among the other factors which may affect future performance are:
competitive market conditions and resulting effects on sales and pricing;
increases in raw-material costs that cannot be recovered in product
pricing; and global economic factors, including difficulties entering new
markets and general economic conditions such as inflation, interest rates
and credit availability. The company makes these statements as of the date
of this disclosure, and undertakes no obligation to update them.
